Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 55/100

Failure Rate

16.7%

1 terminated/withdrawn out of 6 trials

Success Rate

83.3%

-3.2% vs industry average

Late-Stage Pipeline

33%

2 trials in Phase 3/4

Results Transparency

40%

2 of 5 completed trials have results

Key Signals

2 with results

Enrollment Performance

Analytics

Phase 2

2(33.3%)

Phase 3

2(33.3%)

N/A

2(33.3%)

6Total

Phase 2(2)

Phase 3(2)

N/A(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials

NCT02465320Phase 2Completed

COL-1077 (Lidocaine Bioadhesive Gel, 10%) in Women Undergoing Transvaginal Pipelle-Directed Endometrial Biopsy

Role: lead

NCT00343265Not ApplicableCompleted

Vaginal Progesterone Versus Placebo in Multiple Pregnancy

Role: collaborator

NCT01206998Not ApplicableWithdrawn

Vaginal Progesterone as a Treatment for Women Active Preterm Labor

Role: collaborator

NCT00615550Phase 3Completed

PREGNANT Short Cervix Trial

Role: lead

NCT00651313Phase 2Completed

Efficacy and Safety Study of Lidocaine Vaginal Gel for Recurrent Dysmenorrhea (Painful Periods)

Role: lead

NCT00086177Phase 3Completed

Vaginal Progesterone to Reduce the Risk of Another Preterm Birth

Role: lead

All 6 trials loaded